| Species |
Cynomolgus |
| Protein Construction |
MMP-8 (Phe21-Ser467)
Accession # XP_005579523.2 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized MMP-8, His, Cynomolgus at 5μg/ml (100μl/well) on the plate can bind AntiMMP8 Antibody, hFc Tag. Test result was comparable to standard batch. Measured by its ability to cleave a fluorogenic peptide substrate McaKPLGLDpaARNH2. The specific activity is >200 pmol/min/μg. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
52.27 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Alteration of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) expression has been studied for various cardiac diseases, including dilated cardiomyopathy (DCM), with the significance of surrogate markers of extracellular matrix (ECM) remodeling. MMP-8 was identified only in myocardiocytes, while MMP-9 and TIMP-2 were present in both myocardiocytes and stroma, but with different intensity. The increasing intensity of MMP-8 and TIMP-2 immunoreactions was significantly associated with low HCS. |
| Synonyms |
PMNL-CL; CLG1; MMP8; Collagenase 2; PMNL-CL; HNC |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
